Some of the leading companies in the EGFR-NSCLC therapeutics market include Takeda, Abbvie, Yuhan Corporation/ Janssen Research & Development, Novartis, Janssen Research & Development, and others are involved in developing drugs for EGFR-NSCLC.
DelveInsight's "Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the EGFR-NSCLC market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The EGFR-NSCLC market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC): An Overview
Lung cancer mainly begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. Cancer cells are called metastases when they spread from one organ to another. There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas, and several other types that occur less frequently, including adenosquamous carcinomas and sarcomatoid carcinomas.
EGFR is a member of the ErbB family of receptor tyrosine kinases (RTK). Activation of the receptor initiates a cascade of downstream signaling molecules, leading to cell growth and survival. This process is tightly regulated in non-transformed cells. However, constitutive activation of these pathways leads to dysregulated cell growth and proliferation, angiogenesis, and metastasis while repressing apoptosis. Genomic damage can introduce mutations that mimic kinase activation or result in higher expression levels of EGFR. Several treatment options are available to treat this condition in the seven major markets. Typically, chemotherapy, targeted treatments, and immunotherapy—alone or in combination—are used to treat lung cancer.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Key Facts
-
The United States had 227,800+ incident cases of Lung Cancer in 2020, of which ~85% were NSCLC cancer patients (GLOBOCAN, n.d.)
-
Among the European 5 countries, Germany had the highest number of cases of NSCLC. Furthermore, Japan accounted for about 117,700+ cases in 2020.
-
DelveInsight’s analysts have estimated that in 2020, there was over 38,000+ incident cases of EGFR mutation in the United States.
-
The majority (i.e., ˜85%) of EGFR mutations are classic exon 19 deletions and the L858R point mutation), which are clearly defined as strong indicators of good clinical response to EGFRi. Low-frequency mutations, including point mutations, deletions, insertions, and duplications, are seen in exons 18–25 of the EGFR gene (˜15%) in NSCLC and are linked to inferior responses to EGFRi (Harrison et al., 2020).
-
In histology-specific cases, Adenocarcinoma accounts for the highest number of cases, i.e., approximately 47%, followed by Squamous Cell Carcinoma and Large Cell Carcinoma.
-
According to DelveInsight's assessment, 7 out of 10 patients in the United States had metastatic NSCLC (Stage IIIb and IV).
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted EGFR-NSCLC market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the EGFR-NSCLC market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Epidemiology, Segmented by -
-
Total Incidence of NSCLC in the 7MM (2019–2032)
-
Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2019–2032)
-
Total Incident cases of NSCLC patients by Histology in the 7MM (2019–2032)
-
EGFR mutation-specific cases in the 7MM (2019–2032)
-
Total EGFR-NSCLC cases in the 7MM (2019–2032)
-
EGFR-NSCLC Treated cases in the 7MM (2019–2032)
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the EGFR-NSCLC market or expected to be launched during the study period. The analysis covers the EGFR-NSCLC market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the EGFR-NSCLC pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Major Clinical, Commercial, and Regulatory Developments in the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Therapeutics Market:
-
In September 2018, the US FDA approved Pfizer’s Vizimpro (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
-
In May 2021, the US FDA granted the accelerated approval of Rybrevant (amivantamab-vmjw,Janssen) for treating adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. Rybrevant is the first fully human, bispecific antibody approved for treating patients with NSCLC that targets EGFR exon 20 insertion mutations.
-
In September 2021, US FDA approved Exkivity (Mobocertinib, Takeda) to treat adult patients with locally advanced or metastatic NSCLC. It is also the first and only approved oral therapy specifically designed to target EGFR Exon20 insertion mutations.
Learn How the EGFR-NSCLC Market Will Evolve and Grow by 2032 @
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Therapeutics Analysis
The present market of EGFR-positive NSCLC is mainly dominated by Tagrisso (osimertinib); other treatment regimens like platinum-based chemotherapy, first and second generations TKIs, and Vizimpro (dacomitinib) are also contributing to the market size. To improve the treatment scenario, several major pharma and biotech giants are actively working in the therapeutics market.
The Leading Companies in the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Therapeutics Market Include:
-
AstraZeneca
-
Pfizer
-
Takeda
-
Janssen
-
Abbvie
-
Yuhan Corporation
-
Novartis
-
Daiichi Sankyo
And Many Others
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Therapies Covered in the Report Include:
-
Nazartinib (EGF816): Novartis Pharmaceuticals
-
Telisotuzumab Vedotin (Teliso-V): Abbvie
-
Patritumab Deruxtecan (HER3-DXd): Daiichi Sankyo
-
Lazertinib: Yuhan Corporation/ Janssen Research & Development
And Many More
The positive results of investigational products and a robust pipeline for EGFR-NSCLC bring a positive ray of hope for a better treatment pattern in the market in the coming years. The current scenario also anticipates a positive shift in the market for a study period (2019–2032).
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. EGFR-NSCLC Competitive Intelligence Analysis
4. EGFR-NSCLC Market Overview at a Glance
5. EGFR-NSCLC Disease Background and Overview
6. EGFR-NSCLC Patient Journey
7. EGFR-NSCLC Epidemiology and Patient Population (In the US, EU5, and Japan)
8. EGFR-NSCLC Treatment Algorithm, Current Treatment, and Medical Practices
9. EGFR-NSCLC Unmet Needs
10. Key Endpoints of EGFR-NSCLC Treatment
11. EGFR-NSCLC Marketed Products
12. EGFR-NSCLC Emerging Drugs and Latest Therapeutic Advances
13. EGFR-NSCLC Seven Major Market Analysis
14. Attribute Analysis
15. EGFR-NSCLC Market Outlook (In US, EU5, and Japan)
16. EGFR-NSCLC Access and Reimbursement Overview
17. KOL Views on the EGFR-NSCLC Market
18. EGFR-NSCLC Market Drivers
19. EGFR-NSCLC Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
